Upregulation of CD44 confers tumorigenicity, metastatic capacity, and drug resistance to primary tumor cells as well as CTCs (Naor et al., 2002; Fitzgerald and McCubrey, 2014). This evidence concerns the gene CD44 and neoplasm.